As a carrier of doxorubicin (Dox), Au NPs coupled with prostate-specific membrane antigen (PSMA) aptamer could specifically bind to target prostate cancer cells that overexpressing PSMA antigen. Here, FOLH1 is linked to prostate carcinoma.